Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pegargiminase by Polaris Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData,...
Pegargiminase by Polaris Pharmaceuticals for Leiomyosarcoma: Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Leiomyosarcoma. According to GlobalData, Phase III...
Pegargiminase by Polaris Pharmaceuticals for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Pegargiminase by Polaris Pharmaceuticals for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to...
Pegargiminase by Polaris Pharmaceuticals for Gliosarcoma: Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Gliosarcoma. According to GlobalData, Phase III...
Pegargiminase by Polaris Pharmaceuticals for Gliosarcoma: Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Gliosarcoma. According to GlobalData, Phase III...
Pegargiminase by Polaris Pharmaceuticals for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Pegargiminase is under clinical development by Polaris Pharmaceuticals and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to...